Drug Trial Radar · NCT06774625
This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Dec 19, 2024
Primary completion
Aug 8, 2025
Study completion Aug 8, 2025
Sponsor
- Lead sponsor
- Latigo BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours? Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain. Participants will: Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up. Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain
Conditions
- Acute Pain, Postoperative
Interventions
LTG-001 High DoseDrug
LTG-001 High Dose
LTG-001 Mid DoseDrug
LTG-001 Mid Dose
LTG-001 Low DoseDrug
LTG-001 Low Dose
PlaceboOther
Placebo
SuzetrigineDrug
Active comparator - Nav1.8 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- SPID 0-12Time frame: 12 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JBR Clinical Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.